Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC

This study is testing a new type of immune cell therapy — called CAR-NK cells — that is engineered to attack lung cancer cells with two specific proteins (MSLN and either EGFR or HER2) for patients with advanced non-small cell lung cancer (NSCLC) who have already tried standard treatments. **You may be eligible if...** - You have advanced non-small cell lung cancer (stage IIIB/IIIC or stage IV) that has progressed after standard chemotherapy and/or immunotherapy - Your tumor tests positive for at least two of these proteins: MSLN, EGFR, or HER2 - You have at least one measurable tumor on scans - You have good overall function (ECOG 0-1) and adequate organ function - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - You have uncontrolled cancer spread to the brain or spinal fluid - You have received gene-modified cell therapy (like CAR-T cells) within the past 3 months - You have previously had severe reactions to similar cell therapies - You have significant lung disease requiring steroids that could interfere with monitoring Talk to your doctor to see if this trial is right for you.